ScoreWhy is Jagsonpal Pharmaceuticals Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 10.03% over the last 5 years
2
Flat results in Dec 25
3
With ROE of 16.9, it has a Very Expensive valuation with a 4.7 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -30.16%, its profits have risen by 19.7% ; the PEG ratio of the company is 1.5
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
5
Below par performance in long term as well as near term
- Along with generating -30.16% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jagsonpal Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
-30.16%
-0.64
46.83%
Sensex
8.49%
0.74
11.41%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.03%
EBIT Growth (5y)
26.90%
EBIT to Interest (avg)
32.56
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
1.31
Tax Ratio
24.93%
Dividend Payout Ratio
58.85%
Pledged Shares
0
Institutional Holding
2.27%
ROCE (avg)
36.15%
ROE (avg)
16.16%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
28
Industry P/E
32
Price to Book Value
4.75
EV to EBIT
22.73
EV to EBITDA
18.87
EV to Capital Employed
10.25
EV to Sales
3.73
PEG Ratio
1.50
Dividend Yield
1.39%
ROCE (Latest)
44.66%
ROE (Latest)
16.86%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
ROCE(HY)
Highest at 21.66%
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 159.24 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jagsonpal Pharma
Cash and Cash Equivalents - Half Yearly
Highest at Rs 159.24 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
